MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.020
-0.190
-8.60%
Opening 12:29 09/16 EDT
OPEN
2.180
PREV CLOSE
2.210
HIGH
2.180
LOW
2.020
VOLUME
92.94K
TURNOVER
--
52 WEEK HIGH
8.16
52 WEEK LOW
1.840
MARKET CAP
79.15M
P/E (TTM)
-1.3374
1D
5D
1M
3M
1Y
5Y
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 08/26 13:46
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
BRIEF-Oncosec Medical Says Effective Immediately, Oncosec's Interim CEO, Mr. Brian Leuthner, Will Be Leaving Company
reuters.com · 08/16 20:51
OncoSec Provides Leadership Update
and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consisting of three board members, , Ph.D., , M.D. and , Ph.D., MBA, to lead all development efforts,...
PR Newswire - PRF · 08/16 20:01
Stocks That Hit 52-Week Lows On Monday
    Monday morning saw 115 companies set new 52-week lows.
Benzinga · 07/26 14:09
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, and Senior Vice President, Chief Clinical Development Officer, Sandra Aung, Ph.D., will participate in a f...
PR Newswire · 07/26 12:30
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCS. Analyze the recent business situations of OncoSec Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCS stock price target is 10.75 with a high estimate of 12.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 6.94M
% Owned: 17.71%
Shares Outstanding: 39.19M
TypeInstitutionsShares
Increased
15
322.97K
New
7
141.76K
Decreased
10
1.06M
Sold Out
7
195.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.04%
Pharmaceuticals & Medical Research
-0.43%
Key Executives
Chairman/Independent Director
Margaret Dalesandro
Chief Accounting Officer/Vice President - Finance/Controller
Robert Delaversano
Vice President - Business Development
Joe Smith
Director
Joon Kim
Director
Kevin Smith
Director
Yuhang Zhao
Director
Chao Zhou
Independent Director
James Demesa
Independent Director
Herbert Lyerly
Independent Director
Robert Ward
No Data
  • All
  • Financials
  • Insiders
More
About ONCS
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company’s lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCS stock methods without spending real money on the virtual paper trading platform.